Facial Atrophy and Loss of Contour
Conditions
Keywords
Microsized Fat Tissue, Adipose Tissue, Facial Contouring, Fat Transfer
Brief summary
This is an open label multi-center study with the aim of evaluating the efficacy of adipose tissue processed with the SyntrFuge™ system in facial aesthetics and contouring. Patients will be enrolled to the treatment group with adipose tissue processed with the SyntrFuge™ system followed by an injection of autologous microsized adipose tissue in the treatment sites.
Interventions
DEVICESyntrFuge System
Microsized Adipose Tissue
Sponsors
Syntr Health Technologies, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subjects aged of 18-70 years old 2. Willing and able to read and sign the informed consent and other study materials 3. Written informed consent has been obtained prior to any study-related procedures 4. Subjects are ambulatory 5. Ability to follow study instructions and complete study assessment tools including the subject diary 6. Females of childbearing potential must have a negative urine pregnancy test result and not be lactating 7. Agree to not undergo other treatments or cosmetic procedures in the treatment area during the study such as facial laser treatments, botulinum toxin, hyaluronic acid injections, any other permanent or semi-permanent facial fillers 1.5.2
Exclusion criteria
1. Subjects without decisional capacity 2. Subjects unable to give informed, written consent 3. Subjects with active infection (redness, swelling, pain, suppuration) 4. Subjects with any uncontrolled systemic disease 5. Subjects with a history of severe allergic/anaphylactic reactions or multiple allergies 6. Subjects with conditions within the treatment area including acne, scarring, acute lupus erythematosus, dermatitis, or melasma 7. Subjects planning to become pregnant, are pregnant, or are breast-feeding 8. Subjects with history or current evidence of drug or alcohol abuse within 12 months prior to screening visit 9. Subjects who have undergone temporary facial dermal filler injections with hyaluronic acid-based fillers within 12 months in the treatment area. Have had neuromodulator injections, mesotherapy, or resurfacing (laser or other ablative or non-ablative procedures) within 5 months prior to entry in the study or be planning to undergo any of these procedures at any time during the study. 10. Subjects who have undergone facial plastic surgery (except for rhinoplasty or a brow lift), tissue grafting, or tissue augmentation with silicone, fat, or other permanent or semi-permanent dermal fillers or be planning to undergo any of these procedures affecting the treatment area, at any time during the study that may interfere with the study procedure and results 11. Subjects who have active autoimmune disease 12. Subjects who are unwilling to undergo fat graft injections 13. Subjects with current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study 14. Subjects who have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs, e.g., aspirin, ibuprofen), or other substances known to increase coagulation time from 10 days pre- to 3 days post injection. A wash out period of 10 days is allowed 15. Subjects who have undergone immunosuppressive therapy, chemotherapy, biologics or systemic corticosteroids within 3 months prior to each study visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| FaceQ Satisfaction surveys | 6 months | Change from baseline in FACE-Q Satisfaction with questionnaire score for the treated regions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Global Aesthetic Improvement Scale (GAIS) | 6 months | Change in facial regions characteristics as measured by the Global Aesthetic Improvement Scale (GAIS) form from baseline |
| Investigator's Satisfaction Scale | 6 months | Change in facial regions characteristics as measured by the Investigator's Satisfaction Scale form from baseline |
Countries
United States
Outcome results
None listed